Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
46 hedge funds and large institutions have $188M invested in Allena Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less funds holding
Funds holding: 49 → 46 (-3)
18% less capital invested
Capital invested by funds: $231M → $188M (-$42.5M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$11.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$316K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$306K |
| 4 |
State Street
Boston,
Massachusetts
|
+$295K |
| 5 |
Squarepoint
New York
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.85M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.13M |
| 3 |
Millennium Management
New York
|
-$2.86M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$968K |
| 5 |
SIM
Spark Investment Management
New York
|
-$208K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
51
Prelude Capital Management
New York
| – | -$14K | -1,100 | Closed |
|
52
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$11K | -821 | Closed |
|
|
CHP
53
Cable Hill Partners
Portland,
Oregon
| – | -$7K | -500 | Closed |
|
|
PIA
54
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$3K | -201 | Closed |
|
ALNA Hedge Fund Activity: Q3 2018 in Review
46 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q3 2018, worth a combined $188M — down 18% from $231M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ALNA and 5 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was Morgan Stanley, adding an estimated $11.4M. The largest seller was Wellington Management Group, exiting entirely with an estimated $8.85M sold.
- 46 institutional investors held Allena Pharmaceuticals (ALNA) as of Q3 2018, down from 49 in Q2 2018.
- Funds reported $188M of Allena Pharmaceuticals stock for Q3 2018, down 18% quarter-over-quarter.
- 5 funds opened new Allena Pharmaceuticals positions in Q3 2018 and 8 closed out, a net change of -3 holders.
- The largest Allena Pharmaceuticals buyer in Q3 2018 was Morgan Stanley, an estimated $11.4M added.
- The largest Allena Pharmaceuticals seller in Q3 2018 was Wellington Management Group, an estimated $8.85M sold.
Based on aggregated 13F filings for Q3 2018.